North America IVF Devices and Consumables Market Size, Share & Trends Analysis Report By Product Type (IVF Devices Incubators Micromanipulators Cryopreservation Equipment Imaging Systems (e.g., Time-Lapse Imaging) Others (IVF Workstations, Laser Systems) , IVF Consumables Culture Media Petri Dishes and Plates Catheters Syringes and Needles Disposable Gloves Other Consumables (Pipettes, Vials, Straws, etc.) ), By Application (Assisted Reproductive Technology (ART) , Fertility Clinics , Research and Academic Institutes , Hospitals and Surgical Centers ), By Country (U.S., Canada) and Forecast, 2026-2034

North America IVF Devices and Consumables Market Trends

Automation, Time-Lapse Imaging and Data-Driven Embryo Assessment Accelerate Laboratory Modernization

IVF laboratories are shifting toward integrated incubation, continuous imaging, electronic witnessing and AI-assisted embryo assessment. U.S. ART procedure volume reached 435,426 cycles in 2022, compared with 413,776 in 2021, an increase of about 5.2%. Single-embryo transfers represented 85.9% of embryo transfers, reinforcing demand for precise embryo evaluation and controlled culture environments.

Technology development increasingly combines time-lapse videos with machine-learning models. A 2025 research dataset used more than 2,500 time-lapse videos for automated embryo grading, while another published framework evaluated 13,568 frames for embryo-related biomarker detection. These advances support higher utilization of imaging systems, integrated incubators and digital workflow platforms across high-volume ART laboratories.

North America IVF Devices and Consumables Market Drivers

Rising ART Procedure Volumes Expand Laboratory Equipment and Recurring Consumable Requirements

Expanding treatment volumes directly increase utilization of culture media, dishes, pipettes, needles, catheters and cryopreservation supplies. U.S. ART cycles increased from 306,197 in 2018 to 435,426 in 2022, representing growth of approximately 42.2%. CDC data also show a 37.5% live-birth-delivery rate per ART cycle and an average ART patient age of 36.3 years, supporting continued investment in sophisticated laboratory workflows.

North America IVF Devices and Consumables Market Restraints

High Treatment Costs and Uneven Access Restrict Procedure Expansion

Affordability remains a structural constraint because IVF requires laboratory infrastructure, pharmaceuticals, specialized staff and repeated consumable utilization. Industry commentary has cited U.S. IVF-cycle costs exceeding USD 25,000, while CDC reporting historically includes a 6.0%–11.8% range of nonreporting clinics among all fertility clinics. These factors create accessibility and measurement gaps despite the expanding treatment base.

North America IVF Devices and Consumables Market Opportunities

Automation and AI-Based Embryology Create New High-Value Equipment Opportunities

Digital embryo assessment, automated laboratory workflows and genetic-analysis platforms create opportunities beyond conventional incubators and consumables. CooperSurgical states that its PGTai platform has been applied to more than 350,000 embryos and uses a continuously growing dataset of approximately 10,000 samples. Combined with roughly 500 ART clinics operating in the United States, technology penetration across imaging, witnessing and analytical systems presents a substantial equipment-upgrade opportunity.

Challenges in North America IVF Devices and Consumables Market

Laboratory Capacity and Skilled Embryologist Availability Must Keep Pace with Treatment Volume

ART laboratories require trained embryologists alongside increasingly sophisticated equipment. U.S. procedure volumes expanded by about 42.2% between 2018 and 2022, reaching 435,426 cycles, while around 500 clinics currently provide ART services. In response to workforce requirements, ASRM announced its Clinical Embryology Learning Laboratory program in 2025, with enrollment opening in July 2025 and its first cohort beginning during the same year.

North America IVF Devices and Consumables Market Segmentation

The industry is segmented by product type, application, end use, technology and distribution channel. Product-level 2026 data show devices commanding approximately 60.1%, compared with about 39.9% for consumables. Numerical market values and CAGRs are reported only where supplied in the mandatory dataset; no unsupported allocations have been created for application, end-use, technology or channel categories.

By Product Type

IVF Devices: IVF devices were valued at USD 834.01 million in 2025 and USD 979.46 million in 2026, with the category forecast to reach USD 3,544.18 million by 2034 at a 17.44% CAGR. The segment includes incubators, micromanipulators, cryopreservation equipment, imaging systems, workstations and laser systems.

IVF devices are the largest supplied product category, representing approximately 60.1% of the 2026 product-level total. Demand is supported by laboratory modernization and integration of incubation, imaging and micromanipulation functions.

IVF Consumables: Consumables increase from USD 552.31 million in 2025 to USD 649.85 million in 2026 and USD 2,386.95 million by 2034, representing the fastest supplied product CAGR of 17.66%.

The category comprises culture media, dishes, plates, catheters, syringes, needles, gloves, pipettes, vials and straws. Its approximately 39.9% 2026 contribution reflects recurring utilization during retrieval, fertilization, embryo culture, cryopreservation and transfer.

By Application

Applications comprise ART, fertility clinics, research and academic institutes, and hospitals and surgical centers. ART is the fundamental procedural application: CDC recorded 435,426 U.S. ART cycles in 2022, with 37.5% resulting in live-birth delivery.

No application-level revenue or CAGR figures were supplied; therefore, numerical allocations across these four categories have not been fabricated.

By End Use

End users include fertility clinics, hospitals, research laboratories and diagnostic centers. Approximately 500 U.S. clinics currently provide ART services, illustrating the scale of the specialist fertility-clinic customer base.

No end-use-specific market values or CAGRs were provided in the mandatory dataset, preventing defensible identification of a revenue-leading or fastest-growing end-use category.

By Technology

Technology segmentation includes conventional IVF, ICSI, cryopreservation techniques and time-lapse imaging. Adoption is shifting toward controlled embryo culture and continuous monitoring; 85.9% of U.S. embryo transfers in 2022 were single-embryo transfers.

No technology-level revenue or CAGR figures were supplied. Consequently, market values have not been assigned to ICSI, cryopreservation or time-lapse imaging.

By Distribution Channel

Distribution comprises direct sales, distributors and dealers, and online sales. Suppliers increasingly combine direct laboratory relationships with digital ordering and distributor coverage; product catalogs can contain dozens of specialized media, pipette, imaging and cryopreservation configurations.

No channel-level revenue or CAGR data were supplied, so percentage dominance and fastest-growing-channel rates are not stated.

North America IVF Devices and Consumables Market Counties Outlook

U.S.

The United States generated USD 1,065.80 million in 2025 and USD 1,250.18 million in 2026, equivalent to approximately 76.8% of the supplied North American country total. Revenue is forecast to reach USD 4,480.82 million by 2034, representing a 17.30% CAGR.

Demand is reinforced by approximately 500 ART clinics and 435,426 ART cycles reported for 2022. IVF is the primary ART procedure, while cryopreservation is also included within ART surveillance definitions.

Canada

Canada increases from USD 320.52 million in 2025 to USD 377.57 million in 2026, accounting for approximately 23.2% of the supplied 2026 country total. The country is projected to reach USD 1,400.11 million by 2034, recording the faster country CAGR of 17.80%.

Canada therefore contributes roughly one-quarter of regional value while expanding slightly faster than the United States. Demand spans fertility clinics, hospitals, embryo laboratories and cryopreservation operations, although no defensible national production-volume split was supplied.

Top players in North America IVF Devices and Consumables Market

• CooperSurgical, Inc.
• Vitrolife AB
• Hamilton Thorne / Nexpring Health
• Thermo Fisher Scientific Inc.
• Esco Medical
• Nikon Corporation
• FUJIFILM Irvine Scientific
• Genea Biomedx
• Cook Medical
• Planer PLC
• IVFtech
• Gynemed
• Gynétics
• Microptic
• Kitazato Corporation

Top Two Companies

• CooperSurgical

Company-specific percentage share is not disclosed in the supplied dataset and has therefore not been estimated. CooperSurgical maintains a broad fertility portfolio spanning media, dishes, sperm-selection devices, catheters, genetic testing and ART workflow products. The company reports more than600 clinically relevant medical devicesacross its broader women’s-health offering, while its PGTai platform has tested over350,000 embryos. Its North American positioning is strengthened by direct exposure to the large U.S. ART ecosystem and an extensive fertility product portfolio.

• Vitrolife

Company-specific percentage share is likewise not available from the mandatory dataset. Vitrolife competes across culture media, labware, micromanipulation pipettes, EmbryoScope time-lapse systems, laser and imaging platforms, embryo-transfer products and cryopreservation solutions. Its2025product catalogue spans the IVF workflow from oocyte retrieval through embryo evaluation, transfer and cryopreservation. The company has also emphasized automation and U.S. expansion as strategic priorities, positioning it directly against established North American fertility-technology suppliers.

Recent Developments in North America IVF Devices and Consumables Market

• 2025:Hamilton Thorne became part ofNexpring Health, combining Hamilton Thorne, Cook Reproductive Health, Planer, IVFtech, Gynemed, Gynétics, Microptic, TekEvent and Embryotech.
• 2025:ASRM launched its Clinical Embryology Learning Laboratory with SRBT and support from CooperSurgical, with enrollment opening inJuly 2025.
• 2025:CooperSurgical supported an IVF grant initiative providingfive USD 15,000 grants, plusUSD 1,000per recipient toward PGT with ICSI.
• 2025:Vitrolife's product portfolio continued to integrate EmbryoScope time-lapse systems, Octax laser/imaging platforms, genomics, cryopreservation and electronic witnessing across the IVF laboratory workflow.

Research Methodology

The analysis uses the supplied mandatory country and product datasets as the exclusive quantitative basis for 2025, 2026 and 2034 revenue forecasts and corresponding CAGRs. Percentage contributions were calculated directly from supplied totals: the U.S. and Canada represent approximately 76.8% and 23.2%, respectively, of the 2026 country total, while IVF devices and consumables represent approximately 60.1% and 39.9% of the separate 2026 product-level total. External primary and industry sources were used only for operational context, procedure volumes, technology adoption and company developments. Because the supplied country and product tables contain different 2026 and 2034 totals, each table was analyzed independently rather than altering or reconciling the mandatory figures.